Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Centessa Pharmaceuticals (CNTA)
NASDAQ:CNTA
RESEARCH TOOLSreports
Centessa Pharmaceuticals (CNTA) Stock Price & Analysis
71 Followers
CNTA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.15 - $12.45
Previous Close$9.43
Volume234.73K
Average Volume (3M)246.91K
Market Cap
$947.55M
Enterprise Value$802.91M
Total Cash (Recent Filing)$230.18M
Total Debt (Recent Filing)$85.54M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Aug 12, 2024EPS Estimate
-$0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.42
Shares Outstanding113,044,244
10 Day Avg. Volume278,455
30 Day Avg. Volume246,910
Standard Deviation0.18
R-Squared0.16
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)4.78
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.12K
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.73
Forecast
1Y Price Target
$13.33Price Target Upside41.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Centessa Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Financial StabilityCNTA ended 1Q24 with approximately $230M cash and equivalents, providing runway into mid-2026.
LeadershipThe company hired John Crowley, CPA as its new CFO, who brings over 20 years of global finance and operational experience in the life sciences industry.
Pipeline DevelopmentORX750 recently cleared IND and FIH trial initiation, potentially delivering a best-in-class profile with a safety profile without visual disturbances.
Bears Say
Efficacy LimitationALKS2680 efficacy may be limited by the saturation of PK at ~15mg dose.
Safety ConcernsThe safety events (visual disturbance, pollakiuria) may impact broad uptake of ALKS2680.
Side EffectsCompetitor TAK-861 requires BID dosing with frequent urination/insomnia as common side effects.
---
Ownership Overview
27.72% Insiders
6.41% Mutual Funds
21.60% Other Institutional Investors
44.27% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CNTA FAQ
What was Centessa Pharmaceuticals’s price range in the past 12 months?
Centessa Pharmaceuticals lowest stock price was $5.15 and its highest was $12.45 in the past 12 months.
What is Centessa Pharmaceuticals’s market cap?
Currently, no data Available
When is Centessa Pharmaceuticals’s upcoming earnings report date?
Centessa Pharmaceuticals’s upcoming earnings report date is Aug 12, 2024 which is in 21 days.
How were Centessa Pharmaceuticals’s earnings last quarter?
Centessa Pharmaceuticals released its earnings results on May 13, 2024. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.426 by $0.046.
Is Centessa Pharmaceuticals overvalued?
According to Wall Street analysts Centessa Pharmaceuticals’s price is currently Undervalued.
Does Centessa Pharmaceuticals pay dividends?
Centessa Pharmaceuticals does not currently pay dividends.
What is Centessa Pharmaceuticals’s EPS estimate?
Centessa Pharmaceuticals’s EPS estimate is -$0.39.
How many shares outstanding does Centessa Pharmaceuticals have?
Centessa Pharmaceuticals has 113,044,240 shares outstanding.
What happened to Centessa Pharmaceuticals’s price movement after its last earnings report?
Centessa Pharmaceuticals reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.426. Following the earnings report the stock price went up 2.378%.
Which hedge fund is a major shareholder of Centessa Pharmaceuticals?
Among the largest hedge funds holding Centessa Pharmaceuticals’s share is Perceptive Advisors LLC. It holds Centessa Pharmaceuticals’s shares valued at 35M.
---
Centessa Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.33 (41.36% Upside)
$13.33 (41.36% Upside)
Blogger Sentiment
Bullish
CNTA Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 4.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 7.8%
Last 30 Days ▼ 11.2%
Last 30 Days ▼ 11.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.90%
12-Months-Change
Fundamentals
Return on Equity
-54.51%
Trailing 12-Months
Asset Growth
-18.74%
Trailing 12-Months
Company Description
Centessa Pharmaceuticals
Centessa Pharmaceuticals PLC is a pharmaceutical company. Its portfolio consists of preclinical to phase 3 uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. Some of its products include Vasopressin V2 Receptor Inhibitor (Lixivaptan), BMP9 Engineered Variant (MGX292), OX2R Agonist (Oral) among others.
---
CNTA Stock 12 Month Forecast
Average Price Target
$13.33
▲(41.36% Upside)
Technical Analysis
Best Analysts Covering CNTA
1 Year
1 Year Success Rate
10/11 ratings generated profit
1 Year Average Return
+29.80%
assigned a buy rating 2 months ago
Copying Kostas Biliouris's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +29.80% per trade.
---